No Clinically Significant Interaction Between Sildenafil and Eliquis
There is no clinically significant drug interaction between sildenafil and Eliquis (apixaban) that requires dose adjustment or avoidance of concurrent use. These medications can be safely prescribed together with appropriate monitoring.
Mechanism and Evidence
FDA Drug Label Information
The official Eliquis prescribing information does not list sildenafil or other phosphodiesterase-5 (PDE5) inhibitors as contraindicated or requiring dose adjustment 1. The FDA label specifically addresses drug interactions with apixaban, focusing on:
- Combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) - which require dose reduction 1
- Combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) - which should be avoided 1
Sildenafil does not fall into either category.
Pharmacokinetic Considerations
Apixaban is metabolized primarily via CYP3A4 (with minor contributions from other pathways) and is a substrate of P-glycoprotein (P-gp) 1. While in vitro studies have demonstrated that PDE5 inhibitors including sildenafil can inhibit P-gp-mediated efflux of apixaban 2, this laboratory finding has not translated into clinically significant interactions in real-world use.
The key distinction is that sildenafil is neither a strong CYP3A4 inhibitor nor a combined P-gp and strong CYP3A4 inhibitor - the two categories that require apixaban dose adjustment 1.
Clinical Practice Guidance
Safe Concurrent Use
- Continue both medications without dose adjustment in patients requiring anticoagulation and treatment for erectile dysfunction
- Monitor for bleeding as you would with any patient on apixaban, particularly if other bleeding risk factors are present 1
- Avoid nitrates when prescribing sildenafil, as this represents a true contraindication due to severe hypotension risk 3, 4
Important Caveats
The primary bleeding risk with apixaban comes from:
- Antiplatelet agents (aspirin, clopidogrel) - significantly increase bleeding risk 1
- NSAIDs - increase bleeding risk through pharmacodynamic interaction 1
- Other anticoagulants - additive anticoagulant effects 1
Sildenafil does not fall into these high-risk categories.
Blood Pressure Considerations
When prescribing sildenafil to patients on antihypertensive medications (which many patients on anticoagulants may be taking), exercise caution with:
- CYP3A4 inhibitors like diltiazem or verapamil - may increase sildenafil levels and hypotension risk 4
- Nitrates - absolute contraindication 4
- Alpha-blockers - may potentiate hypotensive effects
This is a blood pressure concern, not an anticoagulation interaction.
Bottom Line
Prescribe sildenafil and apixaban together without dose adjustment. The theoretical P-gp interaction observed in laboratory studies 2 has not resulted in clinically significant bleeding complications in practice. Standard bleeding precautions for apixaban apply, with particular attention to avoiding concurrent antiplatelet agents and NSAIDs rather than PDE5 inhibitors 1, 5.